We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.

The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The FDA declared the end of the shortage of Novo Nordisk’s Wegovy and Ozempic, impacting compounding pharmacies selling ...

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

But 25-year-old Madison Burgess has thrown caution to the wind by opting to micro-dose the drug. The Michigan native revealed ...

The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...

Though more research is needed to understand who might benefit from GLP-1 agonists for addiction, early studies suggest that the approach holds promise.

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

David Ricks said drugs like Mounjaro and Zepbound are priced to reflect the costs involved, patent expiry, and the enormous ...